

Seeks long-term capital appreciation.

Tickers A: HGHAX C: HGHXC F: HGHFX I: HGHIX R3: HGHRX
R4: HGHSX R5: HGHTX R6: HGHVX Y: HGHYX

Inception Date 05/01/2000

Morningstar® Category Health

Lipper Peer Group Global Health/Biotechnology

Performance (%)							
Class	QTD	YTD	Average Annual Total Returns				SI
			1 Year	3 Year	5 Year	10 Year	
R3	8.56	7.89	26.13	17.20	14.89	15.71	12.37
R4	8.66	8.06	26.50	17.55	15.23	16.05	12.62
R5	8.72	8.23	26.86	17.90	15.58	16.40	12.86
R6	8.78	8.29	27.00	18.02	15.68	16.51	12.92
Y	8.72	8.23	26.90	17.96	15.65	16.50	12.92
S&P Composite 1500 Health Care Index	8.17	11.81	28.88	16.95	14.52	15.91	—
Morningstar Category	7.18	7.95	30.16	16.10	15.71	15.27	—
Lipper Peer Group	8.94	8.01	25.70	16.38	13.11	14.30	—

Share Class Inception: R3, R4, R5 - 12/22/06; R6 - 2/28/19; Y - 5/1/00. Performance shown prior to the inception of a class reflects performance and operating expenses of another class(es). Had fees and expenses of a class been reflected for the periods prior to the inception of that class, performance would be different. Since inception (SI) performance is from 5/1/00. Performance and expenses for other share classes will vary. Additional information is in the prospectus.

S&P Composite 1500 Health Care Index comprises those companies included in the S&P Composite 1500 that are classified as members of the GICS health care sector. Indices are unmanaged and not available for direct investment.

Calendar Year Returns (%) Y Shares									
2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
22.97	33.69	-2.65	22.04	-8.17	13.10	26.94	50.09	20.35	8.21

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. For more current performance information to the most recent month ended, please visit hartfordfunds.com.

Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in a fund's full prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

Portfolio Managers from Wellington Management

Ann C. Gallo

Senior Managing Director
Global Industry Analyst
Professional Experience Since 1987

Robert L. Deresiewicz

Senior Managing Director
Global Industry Analyst
Professional Experience Since 1983

Rebecca Sykes, CFA

Senior Managing Director
Global Industry Analyst
Professional Experience Since 2005

Wen Shi, CFA

Managing Director
Global Industry Analyst
Professional Experience Since 2007

The portfolio managers are supported by the full resources of Wellington.

Expenses (%)

	R3	R4	R5	R6	Y
Gross	1.60	1.30	1.00	0.90	1.00
Net	1.60	1.30	1.00	0.90	1.00

¹ Expenses as shown in the Fund's most recent prospectus.

Hartford Healthcare Fund

Subsector Exposure (%)

	Fund		Benchmark	Underweight/Overweight	
	3/31/21	6/30/21	6/30/21	6/30/21	
Biopharma Mid Cap	14	14	2		12
Biopharma Small Cap	8	7	0		7
Health Care Services	22	21	24	-3	
Medical Technology	33	32	36	-4	
Biopharma Large Cap	23	25	37	-12	

Based on sub-adviser's classification of health care subsectors, which includes combining biotechnology and pharmaceuticals in terms of capitalization: biopharma small-cap, biopharma mid-cap, and biopharma large-cap. Excludes cash. May not total to 100% due to rounding.

Top Ten Holdings (%)

as of 3/31/21

UnitedHealth Group, Inc.	8.47
Eli Lilly & Co.	5.14
Pfizer, Inc.	5.10
Thermo Fisher Scientific, Inc.	3.98
Bristol-Myers Squibb Co.	3.36
Abbott Laboratories	3.25
Danaher Corp.	3.24
Boston Scientific Corp.	3.05
AstraZeneca plc	2.45
Edwards Lifesciences Corp.	2.38
Percentage Of Portfolio	40.42

Top Ten Holdings (%)

as of 6/30/21

UnitedHealth Group, Inc.	8.28
Eli Lilly & Co.	5.08
Pfizer, Inc.	5.00
Danaher Corp.	3.51
Bristol-Myers Squibb Co.	3.33
Boston Scientific Corp.	3.09
Abbott Laboratories	2.85
AstraZeneca plc	2.68
Edwards Lifesciences Corp.	2.68
Illumina, Inc.	2.33
Percentage Of Portfolio	38.83

Net Assets	\$1.7 billion
# of Holdings	112
% in Equities	96%
% in Foreign Equities	18%
Beta (3 yrs)	1.06
R Squared (3 yrs)	0.88
Turnover	39%

Holdings Characteristics

	Fund	Benchmark
Price/Earnings	35.0x	16.4x
Price/Book	5.9x	5.2x
EPS Growth Rate	14.7%	10.9%
Return on Equity	9.0%	22.9%
Asset Weighted Market Cap (billions)	\$102.2	\$158.5
Median Market Cap (billions)	\$6.5	\$6.1

Market Cap Distribution (%)

Less than \$2 billion	7
\$2 billion - \$5 billion	9
\$5 billion - \$10 billion	9
Greater than \$10 billion	74
Not Classified	0

Benchmark S&P Composite 1500 Health Care Index

Holdings and characteristics are subject to change. Percentages may be rounded.

Important Risks: Investing involves risk, including the possible loss of principal. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, patent considerations, intense competitive pressures, rapid technological changes, potential product obsolescence, and liquidity risk. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political, economic and regulatory developments. These risks may be greater, and include additional risks, for investments in emerging markets.

Asset Weighted Market Cap is the value of a corporation as determined by the number of outstanding shares of common stock multiplied by the price per share. **Beta** measures the volatility of a portfolio relative to a benchmark. A beta of less than 1.00 indicates lower risk than the market; a beta of greater than 1.00 indicates higher risk than the market. **EPS Growth Rate** is the projected growth rate in earnings per share for the next five years. **Price/Book** is the ratio of a stock's price to its book value per share.

Price/Earnings is the ratio of a stock's price to its earnings per share. **Return on Equity** is the average amount of net income returned as a percentage of shareholder's equity over the past five years. **R Squared** represents the percentage of the portfolio's movement that can be explained by the market. **Turnover** is a percentage of a portfolio's assets that have changed over the course of a year. It is calculated by dividing the average assets during the period by the lesser of the value of purchases or the value of sales during the same period.

Mutual funds are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC (HFMC). Certain funds are sub-advised by Wellington Management Company LLP. HFD and HFMC are not affiliated with any sub-adviser.